Precigen (STU:I5X) Accounts Payable: €4.60 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:I5X Precigen Inc STU:I5X
56 GF Score
Price €6.20
GF Value €13.14
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Precigen Accounts Payable?

Precigen STU:I5X +3.33% 56 Accounts Payable is €4.60 Mil as of Jun. 2026. GuruFocus rates STU:I5X with a GF Score™ of 56/100 and a GF Value™ of €13.14 (Possible Value Trap). The stock has 9 warning signs investors should review.

Precigen's Accounts Payable for the quarter that ended in Jun. 2026 was €4.60 Mil.

Precigen's quarterly Accounts Payable declined from Dec. 2025 (€10.24 Mil) to Mar. 2026 (€2.24 Mil) but then increased from Mar. 2026 (€2.24 Mil) to Jun. 2026 (€4.60 Mil).

Precigen's annual Accounts Payable increased from Dec. 2023 (€1.58 Mil) to Dec. 2024 (€3.37 Mil) and increased from Dec. 2024 (€3.37 Mil) to Dec. 2025 (€10.24 Mil).

Precigen Accounts Payable Historical Data

* Premium members only.

The historical data trend for Precigen's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen Accounts Payable Chart

Precigen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.75 3.84 1.58 3.37 10.24

Precigen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.40 5.34 10.24 2.24 4.60
STU:I5X
56GF Score
Precigen Inc STU:I5X
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precigen Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €4.60 Mil mean?
Precigen (STU:I5X) has a Accounts Payable of €4.60 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Precigen and its competitors.
Is Precigen's Accounts Payable too high?
Precigen's current Accounts Payable is €4.60 Mil. Overall, Precigen has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Precigen's Accounts Payable compare to GLUE and ZBIO?
Precigen's Accounts Payable of €4.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Precigen and its competitors. Precigen's current Accounts Payable is €4.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Possible Value Trap. The stock's GF Value™ is €13.14, compared to a current price of €6.20 — trading 52.8% below its estimated fair value. The current Accounts Payable is €4.60 Mil. Precigen's overall GF Score™ is 56/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Precigen (STU:I5X), the current Accounts Payable is €4.60 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €6.20 is trading 52.8% below its estimated GF Value™ of €13.14. GuruFocus considers Precigen to be Possible Value Trap.

Key valuation signals for STU:I5X:

  • Accounts Payable: €4.60 Mil
  • GF Value™: €13.14 vs. price of €6.20 (52.8% below fair value)
  • GF Score™: 56/100 with 9 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
56GF Score

Get the complete analysis for STU:I5X

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.20
Price
€13.14
GF Value